Abramson JS et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C). ASH 2023;Abstract 611.

Abramson JS et al. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Blood Adv 2023;7(7):1130-6. Abstract

Abramson JS et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study. Blood 2023;141(14):1675-84. Abstract

Ayyappan S et al. Final analysis of the phase 2 ELM-2 study: Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). ASH 2023;Abstract 436.

Belada D et al. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: The phase 1b First-MIND study. Blood 2023;142(16):1348-58. Abstract

Caimi PF et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase 2 LOTIS-2 study. Haematologica 2023;[Online ahead of print]. Abstract

Chavez J et al. 3-Year Analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). ASH 2023;Abstract 894.

Cohen JB et al. Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study. ASH 2023;Abstract 981.

Crombie J et al. Odronextamab demonstrates durable complete responses in patients with diffuse large B-cell lymphoma (DLBCL) progressing after CAR-T therapy: Outcomes from the ELM-1 study. ASH 2023;Abstract 4461.

Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety in the phase II L-MIND study. Haematologica 2024 Feb 1;109(2):553-66. Abstract

Fornecker L et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): A multicenter, open-label, randomized, phase II trial. J Clin Oncol 2023;41(2):327-35. Abstract

Goy A et al. Outcomes of patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an expanded access study. ASH 2023;Abstract 106.

Hawkes E et al. A window study of acalabrutinib & rituximab, followed by chemotherapy & autograft (ASCT) in fit patients with treatment naïve mantle cell lymphoma (MCL): Dirst report of the investigator-initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ trial. ASH 2023;Abstract 735.

Henderson TO et al. AHOD2131: A randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma. ASH 2023;Abstract 3084.

Herrera AF et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic hodgkin lymphoma (HL). ASCO 2023;Abstract LBA4.

Hutchings M et al. Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume. ASH 2023;Abstract 433.

Jerkeman M et al. Initial safety data from the phase 3 POLAR bear trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-pola-mini-CHP and R-mini-CHOP. EHA 2023;Abstract S227.

Karimi Y et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. ASCO 2023;Abstract 7525.

Kumar A et al. A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma. ASH 2023;Abstract 738.

Le Gouill S et al. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica 2024;109(1):343-50. Abstract

Lee H et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced stage classical Hodgkin lymphoma: Efficacy and safety results from the single arm phase 2 study. ASH 2023;Abstract 608.

Linton K et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: First data disclosure from the epcore NHL-1 follicular lymphoma dose-expansion cohort. ASH 2023;Abstract 1655.

Morschhauser F et al. Deciphering the clinical benefit of Pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study. ASH 2023;Abstract 3000.

Morschhauser F et al. TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma. ASH 2023;Abstract 602.

Morschhauser F et al. TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL). ICML 2023;Abstract LBA4.

Neelapu S et al. Axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial. ASH 2023;Abstract 4868.

Neelapu S et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141(19):2307-15. Abstract

Portell C et al. Primary analysis and results of bendamustine, rituximab, and venetoclax (BR-VEN) for initial treatment of mantle cell lymphoma in subjects over 60 years of age (PrE0405). ASH 2023;Abstract 733.

Rutherford SC et al. Nivolumab-AVD is better tolerated and improves progression-free survival compared to BV-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826. ASH 2023;Abstract 181.

Schuster SJ et al. Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: Phase 2 Elara 3-year follow-up. ASH 2023;Abstract 601.

Schuster SJ et al. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal phase II study. ASH 2023;Abstract 603.

Townsend W et al. Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: Final results from the GALLIUM study. Hemasphere 2023;7(7):e919. Abstract

Villasboas JC et al. Results of a second, prespecified analysis of the phase 2 study ELM-2 confirm high rates of durable complete response with odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) with extended follow-up. ASH 2023;Abstract 3041.

Wang M et al. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: Primary analysis results from the randomized phase 3 sympatico study. ASH 2023;Abstract LBA-2.

Wang M et al. Ibrutinib-rituximab and venetoclax (IRV) followed by risk-stratified R-HyperCVAD/MTX in young patients with untreated mantle cell lymphoma — Phase II WINDOW-2 trial. ICML 2023;Abstract 101.

Wang M et al. Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: Primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol 2023;[Online ahead of print]. Abstract

Westin JR et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 2023;389(2):148-57. Abstract